ArticleFrontiers in psychiatry2025
High-intensity transcranial alternating current stimulation combined with pharmacotherapy for adolescent major depressive disorder: a prospective case report study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adolescent major depressive disorder (MDD) presents a growing public health concern due to the limited efficacy of current treatments, while high-intensity transcranial alternating current stimulation (HI-tACS) has shown promise in adults but remains unstudied in adolescents. This study therefore examined the preliminary efficacy and safety of HI-tACS combined with pharmacotherapy for first-episode adolescent MDD, with a primary focus on suicide risk reduction. Methods: In this prospective case series, seven adolescents (aged 12-17 years) diagnosed with MDD received a 4-week intervention combining HI-tACS (77.5 Hz/15 mA, once daily for 20 sessions) with pharmacotherapy. All participants received a standardized pharmacological regimen consisting of sertraline hydrochloride with adjunctive aripiprazole, while oxazepam was permitted as needed for insomnia. Clinical outcomes were assessed at baseline, week 2, and week 4 using the 24-item Hamilton Depression Rating Scale (HAMD-24) and the Patient Health Questionnaire (PHQ-9). Results: After 4 weeks of treatment, 57.1% of patients achieved a clinical response (≥ 50% reduction in HAMD-24 total score) and 14.3% reached remission (HAMD-24 total score ≤ 8). The HAMD-24 total score significantly decreased at Weeks 2 (Z = -2.366, p = 0.018) and Week 4 (Z = -2.196, p = 0.028). PHQ-9 total scores showed more pronounced improvement during the early treatment phase. Suicide risk initially declined but then rose slightly in the later phase. The intervention was well tolerated with no serious adverse events reported. Conclusions: The combination of HI-tACS and pharmacotherapy demonstrated potential early effects in this small cohort of adolescents with MDD, particularly during the initial phase of treatment. These preliminary findings warrant further investigation through large-scale randomized controlled trials to establish efficacy and safety profiles, and to further characterize suicide risk trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.